PVCT Provectus Biopharmaceuticals Inc

USD 0.14 0.00 2.042254
Icon

Provectus Biopharmaceuticals Inc (PVCT) Stock Analysis and Price Targets

COMMON STOCK | Biotechnology | OTC
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 0.14

+0.00 (+2.04)%

USD 0.06B

0.65M

N/A

N/A

Icon

PVCT

Provectus Biopharmaceuticals Inc (USD)
COMMON STOCK | OTC
USD 0.14
0.00 0
Take a Tour
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 0.06B

N/A

USD 0.14

Provectus Biopharmaceuticals Inc (PVCT) Stock Forecast

N/A

Based on the Provectus Biopharmaceuticals Inc stock forecast from 0 analysts, the average analyst target price for Provectus Biopharmaceuticals Inc is not available over the next 12 months. Provectus Biopharmaceuticals Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Provectus Biopharmaceuticals Inc is Bearish, which is based on 1 positive signals and 4 negative signals. At the last closing, Provectus Biopharmaceuticals Inc’s stock price was USD 0.14. Provectus Biopharmaceuticals Inc’s stock price has changed by +6.78% over the past week, +36.57% over the past month and +33.55% over the last year.

No recent analyst target price found for Provectus Biopharmaceuticals Inc
No recent average analyst rating found for Provectus Biopharmaceuticals Inc

Company Overview Provectus Biopharmaceuticals Inc

Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes. The company's lead molecule is rose bengal sodium (RBS). Its clinical development programs include PV-10 for the treatment of ...Read More

10025 Investment Drive, Knoxville, TN, United States, 37932

4

December

USD

USA

Adjusted Closing Price for Provectus Biopharmaceuticals Inc (PVCT)

Loading...

Unadjusted Closing Price for Provectus Biopharmaceuticals Inc (PVCT)

Loading...

Share Trading Volume for Provectus Biopharmaceuticals Inc Shares

Loading...

Compare Performance of Provectus Biopharmaceuticals Inc Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for PVCT

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Provectus Biopharmaceuticals Inc (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NONOF
Novo Nordisk A/S +5.12 (+4.29%) USD456.53B 41.43 4.67

ETFs Containing PVCT

Symbol Name PVCT's Weight Expense Ratio Price(Change) Market Cap
no data

Frequently Asked Questions About Provectus Biopharmaceuticals Inc (PVCT) Stock

Stock Target Advisor's fundamental analysis for Provectus Biopharmaceuticals Inc's stock is Bearish.

PVCT stock's dividend yield is 7.77%. Our analysis grades PVCT stock's dividend yield at A-. This means that PVCT stock's dividend yield is above 90% of the stocks in the Biotechnology sector in the OTC exchange. Based on this PVCT may be a good dividend stock for its sector.

Unfortunately we do not have enough data on PVCT's stock to indicate what its average analyst target is.

Unfortunately we do not have enough data on PVCT's stock to indicate if its overvalued.

The last closing price of PVCT's stock was USD 0.14.

The most recent market capitalization for PVCT is USD 0.06B.

Unfortunately we do not have enough analyst data on PVCT's stock to indicate whether its price will go up or not.

We can't find any ETFs which contains Provectus Biopharmaceuticals Inc's stock.

As per our most recent records Provectus Biopharmaceuticals Inc has 4 Employees.

Provectus Biopharmaceuticals Inc's registered address is 10025 Investment Drive, Knoxville, TN, United States, 37932. You can get more information about it from Provectus Biopharmaceuticals Inc's website at https://www.provectusbio.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...